Analyst Joseph Schwartz from Leerink Partners maintained a Buy rating on Edgewise Therapeutics (EWTX – Research Report) and increased the price target to $44.00 from $42.00. Joseph Schwartz’s rating ...

Edgewise Therapeutics, Inc. ( (EWTX) ) has released its Q3 earnings. Here is a breakdown of the information Edgewise Therapeutics, Inc.

Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today reported financial results for the third quarter of 2024 and recent business highlights.

Wealth Enhancement Group, a national independent wealth management firm with over $96.6 billion in client assets, has announced the acquisition of M&R Capital Management, Inc., an independent RIA in ...

Invesque Inc. (the "Company") today announced its results for the three and nine months ended September 30, 2024. Third Quarter and Recent Highlights As previously announced, on September 23, 2024, ...

DelveInsight's 'Exosomes Pipeline Insight 2024' report provides comprehensive global coverage of available, marketed, and ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

On Wednesday, Piper Sandler maintained its Overweight rating and $51.00 stock price target for Edgewise Therapeutics (NASDAQ:EWTX). The firm expressed continued optimism following a recent discussion ...